Click here to get full coverage on Replimune Group (NASDAQ:REPL) Sees Large Volume Increase - Time to Buy? - MarketBeat

Replimune Group (NASDAQ:REPL) Sees Large Volume Increase - Time to Buy?  MarketBeat

Replimune Group (NASDAQ:REPL) Sees Large Volume Increase - Time to Buy? - MarketBeat

Click here to get full coverage on Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman  PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Click here to get full coverage on $REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82  Nasdaq

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq

Click here to get full coverage on REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug  Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

Click here to get full coverage on Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’  Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Click here to get full coverage on REPL: Launch-ready oncolytic immunotherapy platform targets broad cancer markets with strong clinical data - TradingView — Track All Markets

REPL: Launch-ready oncolytic immunotherapy platform targets broad cancer markets with strong clinical data  TradingView — Track All Markets

REPL: Launch-ready oncolytic immunotherapy platform targets broad cancer markets with strong clinical data - TradingView — Track All Markets

Click here to get full coverage on Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today  Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Click here to get full coverage on Replimune Group (NASDAQ:REPL) Shares Down 6.4% - What's Next? - MarketBeat

Replimune Group (NASDAQ:REPL) Shares Down 6.4% - What's Next?  MarketBeat

Replimune Group (NASDAQ:REPL) Shares Down 6.4% - What's Next? - MarketBeat

Click here to get full coverage on Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman  PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Click here to get full coverage on Notable Monday Option Activity: TTD, REPL, UPST - Nasdaq

Notable Monday Option Activity: TTD, REPL, UPST  Nasdaq

Notable Monday Option Activity: TTD, REPL, UPST - Nasdaq

Click here to get full coverage on Replimune Group (NASDAQ:REPL) Trading Down 5.4% - Should You Sell? - MarketBeat

Replimune Group (NASDAQ:REPL) Trading Down 5.4% - Should You Sell?  MarketBeat

Replimune Group (NASDAQ:REPL) Trading Down 5.4% - Should You Sell? - MarketBeat

Click here to get full coverage on Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman  PR Newswire

Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

Click here to get full coverage on $REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL) - MarketBeat

Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL)  MarketBeat

Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL) - MarketBeat

Click here to get full coverage on $REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on $REPL stock is up 93% today. Here's what we see in our data. | REPL Stock News - Quiver Quantitative

$REPL stock is up 93% today. Here's what we see in our data. | REPL Stock News  Quiver Quantitative

$REPL stock is up 93% today. Here's what we see in our data. | REPL Stock News - Quiver Quantitative

Click here to get full coverage on Hill, Replimune CFO, sells $49k in REPL stock - Investing.com

Hill, Replimune CFO, sells $49k in REPL stock  Investing.com

Hill, Replimune CFO, sells $49k in REPL stock - Investing.com

Click here to get full coverage on Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment?  simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Click here to get full coverage on Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Why Is Replimune Stock (REPL) Up 105% Today?  TipRanks

Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Click here to get full coverage on Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq

Replimune Group (REPL) Price Target Increased by 48.75% to 10.84  Nasdaq

Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq

Click here to get full coverage on BMO Capital Upgrades Replimune Group (REPL) - Nasdaq

BMO Capital Upgrades Replimune Group (REPL)  Nasdaq

BMO Capital Upgrades Replimune Group (REPL) - Nasdaq

Click here to get full coverage on Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism  simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Click here to get full coverage on Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection  Quiver Quantitative

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative

Click here to get full coverage on Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)  Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha

Replimune stock gains on FDA Type A meeting (REPL:NASDAQ)  Seeking Alpha

Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market?  simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Click here to get full coverage on 44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025  Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

Click here to get full coverage on Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman  PR Newswire

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

Click here to get full coverage on PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma  Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

Click here to get full coverage on Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - Yahoo Finance

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months  Yahoo Finance

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - Yahoo Finance

Click here to get full coverage on Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan

Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma  Stock Titan

Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan

Click here to get full coverage on JP Morgan Upgrades Replimune Group (REPL) - Nasdaq

JP Morgan Upgrades Replimune Group (REPL)  Nasdaq

JP Morgan Upgrades Replimune Group (REPL) - Nasdaq

Click here to get full coverage on REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) - GlobeNewswire

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL)  GlobeNewswire

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) - GlobeNewswire

Click here to get full coverage on MTD Gasoline Track Snowblower Snow Blowers New Part) 946-0951A REPL MTD SNOWBLOWER Idler Auger Cable MTD Idler Lawnmower Parts - rasytojai.lt

MTD Gasoline Track Snowblower Snow Blowers New Part) 946-0951A REPL MTD SNOWBLOWER Idler Auger Cable MTD Idler Lawnmower Parts  rasytojai.lt

MTD Gasoline Track Snowblower Snow Blowers New Part) 946-0951A REPL MTD SNOWBLOWER Idler Auger Cable MTD Idler Lawnmower Parts - rasytojai.lt

Click here to get full coverage on Replimune Group (NASDAQ:REPL) Shares Up 10.9% - Should You Buy? - MarketBeat

Replimune Group (NASDAQ:REPL) Shares Up 10.9% - Should You Buy?  MarketBeat

Replimune Group (NASDAQ:REPL) Shares Up 10.9% - Should You Buy? - MarketBeat

Click here to get full coverage on REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is  GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

Click here to get full coverage on Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - PR Newswire

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd  PR Newswire

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - PR Newswire

Click here to get full coverage on Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman - GlobeNewswire

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman  GlobeNewswire

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman - GlobeNewswire

Click here to get full coverage on Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector  Stocktwits

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits

Click here to get full coverage on Replimune stock rises as Cantor Fitzgerald upgrades (REPL) - Seeking Alpha

Replimune stock rises as Cantor Fitzgerald upgrades (REPL)  Seeking Alpha

Replimune stock rises as Cantor Fitzgerald upgrades (REPL) - Seeking Alpha

Click here to get full coverage on Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL)  Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Click here to get full coverage on Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig  GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Click here to get full coverage on Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more  Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Click here to get full coverage on REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on Is Replimune Group (NASDAQ:REPL) A Risky Investment? - 富途资讯

Is Replimune Group (NASDAQ:REPL) A Risky Investment?  富途资讯

Is Replimune Group (NASDAQ:REPL) A Risky Investment? - 富途资讯

Click here to get full coverage on FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection  Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

Click here to get full coverage on Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha

Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ)  Seeking Alpha

Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Replimune stock down after report on drug rejection (REPL)  Seeking Alpha

Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Click here to get full coverage on REPL Stock Drops: A Closer Look - timothysykes.com

REPL Stock Drops: A Closer Look  timothysykes.com

REPL Stock Drops: A Closer Look - timothysykes.com

Click here to get full coverage on REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire

REPL DEADLINE: Replimune Group Investors Should Contact  GlobeNewswire

REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire

Click here to get full coverage on Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance  GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Click here to get full coverage on Vibe Coding Something Useful with Repl.it - KDnuggets

Vibe Coding Something Useful with Repl.it  KDnuggets

Vibe Coding Something Useful with Repl.it - KDnuggets

Click here to get full coverage on REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm  Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

Click here to get full coverage on REPL Stock: An Unexpected Surge or a Bubble?​ - StocksToTrade

REPL Stock: An Unexpected Surge or a Bubble?​  StocksToTrade

REPL Stock: An Unexpected Surge or a Bubble?​ - StocksToTrade

Click here to get full coverage on Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ)  Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting  Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Click here to get full coverage on REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT  GlobeNewswire

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

Click here to get full coverage on Why Is Replimune Stock (NASDAQ:REPL) Exploding? - TipRanks

Why Is Replimune Stock (NASDAQ:REPL) Exploding?  TipRanks

Why Is Replimune Stock (NASDAQ:REPL) Exploding? - TipRanks

Click here to get full coverage on Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha

Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL)  Seeking Alpha

Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...  Yahoo Finance

Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Click here to get full coverage on Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha

Replimune stock rebounds despite downgrades (REPL:NASDAQ)  Seeking Alpha

Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL)  Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Replimune (REPL) Stock Surges on FDA Application Acceptance - GuruFocus

Replimune (REPL) Stock Surges on FDA Application Acceptance  GuruFocus

Replimune (REPL) Stock Surges on FDA Application Acceptance - GuruFocus

Click here to get full coverage on REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after - GlobeNewswire

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after  GlobeNewswire

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after - GlobeNewswire

Click here to get full coverage on REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm  PR Newswire

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire

REPL

Price Chart

Key Statistics

Technicals

About REPL

Latest News

Replimune Group (NASDAQ:REPL) Sees Large Volume Increase - Time to Buy? - MarketBeat

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

$REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers